Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab with short-course radiotherapy followed by surgery in early-stage NSCLC
2020-004413-13Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoint: Major pathological response rate. Started Apr 2021; status: active.
02
Drugs
durvalumabtiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004413-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004413-13.